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(-8.2mmHg, n = 146), valsartan (-7.9mmHg, n = 142) and irbe-
sartan (-9.9mmHg, n = 145), p < 0.05 in each comparison. The
proportion of patients with controlled BP were 56.0% (95%
conﬁdence intervals; 47.4%–64.1%), 41.7% (33.7%–50.2%),
32.6% (24.8%–40.8%), and 52.1% (44.0%–60.8%), with
olmesartan, losartan, valsartan and irbesartan respectively at
week 8 (p < 0.05 olmesartan vs losartan and valsartan). Mean
costs were the same for all options considered, yielding olme-
sartan as the dominant option with a cost per successfully treated
patient lower (92.43€ (88.2€–96.6€)) than with the other drugs;
124.12€ (120.0 €–128.3€), 158.77€ (154.8€–162.8€) and 99.35€
(95.1€–103.6€), for losartan, valsartan and irbesartan, respec-
tively. CONCLUSIONS: Olmesartan showed a more favourable
pharmaco-economic proﬁle than losartan and valsartan in the
short-term treatment of mild to moderate essential hypertension
in Spain. Irbesartan was not statistically inferior than olmesar-
tan. Long-term studies are needed to conﬁrm these ﬁndings.
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OBJECTIVES: Abdominal aortic aneurysm (AAA) is a common
disease, particularly among elderly men. Rupture of AAA is asso-
ciated with high mortality, causing about 1% of all fatalities in
men over 60 years of age. Most patients with ruptured AAA die
before they come to surgery and the overall mortality is about
80%, compared to a reported mortality during elective surgery
of 0–9%. Early detection by screening has therefore been advo-
cated and the objective of this study was to evaluate the long-
term cost-effectiveness of different screening strategies for AAA.
METHODS: A Markov cohort simulation model was developed
and different screening strategies in terms of age and risk pro-
ﬁles of the screened population and re-screening were analysed.
Assumptions and variables in the model were based on a sys-
tematic review of the literature. The cost per life year gained was
used as main outcome measure. RESULTS: The cost per life year
gained for the different screening strategies ranged from $8309
to $14,084 and was estimated to $10,474 when 65-year-old men
were screened once. Sensitivity analyses showed that the results
were robust. Variations of risk of rupture among screened and
non-screened and long-term survival affected the cost-effective-
ness substantially. The cost-effectiveness was rather insensitive to
variations in cost of screening, cost of surgery and attendance
rate. CONCLUSIONS: Screening for AAA may be cost-effective
in 65-year-old men, while screening younger men with a re-
screening could be equally cost-effective with the advantage of
more life years gained. Some aspects need to be characterized in
further detail, particularly quality of life effects related to screen-
ing for AAA, age-speciﬁc natural course of AAA and age-speciﬁc
long term survival.
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OBJECTIVES: Congestive heart failure (CHF) is the leading
cause for hospitalization in the elderly. In a meta-analysis of 
16 randomized controlled trials (RCT) investigating disease
management programs (DMP) in the treatment of CHF, we 
previously demonstrated a statistically signiﬁcant reduction 
in mortality and rehospitalization, but cost-effectiveness of 
DMPs remains uncertain. Therefore, we sought to evaluate life
expectancy and life long medical costs for DMPs. METHODS:
Design: Cost and cost-effectiveness analysis using a 6 state
Markov Model representing the number of prior hospitalizations
(h = 1 to h = 4+) and death. Data sources: Pooled efﬁcacy data
from our meta-analyses of RCTs, SOLVD registry data for age-
dependent hospitalizations and mortality rates adjusted for 
additional beneﬁt from beta-blocker therapy and reimbursement
costs in the Australian health care system. Target population:
Patients that have been admitted with CHF. Time horizon: life-
time. Perspective: societal. Intervention: conventional therapy
and DMP. Outcome measures: Life years gained (LYG) and life-
long direct medical costs. RESULTS: For a population aged 73
at onset of CHF (27% female, 33% on beta-blocker), our model
yielded, on average, a remaining life expectancy of 3.24 years
for conventional therapy and 3.38 years for DMP. Mean undis-
counted lifetime costs per patient were estimated at 11,600€
and 12,700€ respectively. The discounted incremental cost-
effectiveness ratio (ICER) of DMP vs. conventional care was
8813€ per LYG. Assuming the beneﬁt due to DMP lasting for 5
years after the end of the actual intervention would lead to addi-
tional 5 life-months and reduce ICER to 4021€/LYG. CON-
CLUSIONS: Based on our decision analysis, DMPs prolong life,
but increase life-time costs. A cost-saving effect of DMPs as sug-
gested in some original studies could not be conﬁrmed. However,
even under conservative assumptions regarding the duration of
DMP, these programs are cost-effective when compared to other
well-accepted medical interventions in heart disease.
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OBJECTIVES: Sinus Node Disease (SND) is a common indica-
tion for implantation of a permanent pacemaker. In case of 
subsequent development of atrioventricular block (AVB) it is nec-
essary to upgrade atrial pacemaker (AAI) to dual-chamber
(DDD). The aim of the study was to evaluate the inﬂuence of
atrial ﬁbrillation (AF) history on the risk of AVB development in
patients with SND and permanent AAI and its impact on pacing
therapy costs. METHODS: Data of 752 patients with SND who
had AAI implanted between 1993 and 1997 were identiﬁed. The
history of AF was established on the basis of preoperative exam.
The records of patients were examined to ﬁnd cases that required
further procedure to upgrade AAI to DDD. The cost analysis was
performed to assess the strategy of primary DDD implantation
in those patients with SND that would receive AAI as a stan-
dard. The costs taken into consideration were: pacemaker, leads,
implantation procedure, hospitalization. The analysis of sensi-
tivity for main partial costs was performed, future costs were 
discounted. RESULTS: In the whole group of 752pts–144pts
(19.1%) required the upgrade procedure. A total of 417pts
(55.5%) had a history of AF. A total of 105pts had the subse-
quent DDD pacemaker implanted in the AF group (25.2%) and
39 in the group with no AF history (11.6%). There were savings
of 82€ per patient, in the primary AAI implantation arm, in the
whole group and 190€ Euro in the no-AF group whereas both
strategies were equal in the group with AF history. CONCLU-
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SIONS: The risk of AVB in SND patients is increased in cases
with AF history. The strategy of primary AAI implantation in
SND is cost-saving in patients with no history of AF but no such
proﬁt is observed in the group with the history of AF.
CARDIOVASCULAR
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OBJECTIVES: The objective of our study was to assess 
depressive symptomatology (DS) among CVD affected women.
METHODS: Symptomatic women patients suffering from CVD
(CEAP C0 to C4), aged over 18, newly treated by their GP with
a phlebotropic drug were enrolled in the study. Every patient
completed a self-questionnaire including the CES-D scale at day
0, day three and seven. A score over 17 indicates a possible DS,
a score over 23 indicates a probable DS. RESULTS: This analy-
sis includes the ﬁrst 371 patients assessed at day 0, D3 and D7.
The mean age was 45.0 years old (SD = 11, n = 370). The mean
CES-D scores at day 0, D3 and D7, were respectively 14.9 (SD
= 10.2), 13.7 (SD = 8.9) and 12.8 (SD = 10.1). The results high-
light a possible DS in our population (score over 17) for 36.3%,
32.3% and 29.0% respectively at day 0, D3 and D7 (p < 0.01,
n = 328). Patients that have expressed a probable DS were 74 at
inclusion (22.0% of the population); they show a signiﬁcant
improvement of their status assessed by CES-D. From those 74
patients, only 50 still had a score over 23 at D3 and 46 at D7
showing a decrease of 37.8% of the number of patients express-
ing a probable DS (p < 0.0001, n = 74, matched test J0-J7).
CONCLUSIONS: In the study of Rield assessing depressive
symptoms in older women (age 65 to 75), 23.1% of women
reported high depressive symptoms (CES-D score over 16). CVD
result in psychological effects that seriously affect patients’ lives.
Following patient management and the use of a phlebotropic
drug the prevalence of DS decreased rapidly showing evidence
of the relevance of this management.
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OBJECTIVES: The objective of our study was to describe the
proﬁle of French women suffering from Chronic venous disease
(CVD). METHODS: Symptomatic women patients suffering
from CVD (CEAP clinical classes C0 to C4), aged over 18, newly
treated by their GP with a phlebotropic drug were enrolled in
the study. They completed a self-questionnaire including the SF-
12, the CES-D and the CIVIQ scales at day zero, day three and
seven. RESULTS: This analysis includes the ﬁrst 399 patients
assessed at inclusion. Mean age was 45.0 years old (SD = 11, n
= 370). A total of 65.7% have a professional activity, 32% prac-
tice sport, 33% are smokers, 78.4% gave birth already and 50%
are under oral contraceptive. A total of 9.1% wear compression
stockings. At inclusion (n = 374), MCS-12 and PCS-12 were
respectively 44.7 (SD = 10.6) and 46.4 (SD = 8.4); and the mean
CIVIQ score was 32.6 (SD = 1.1). Concerning the CES-D, the
mean score were 14.9 (SD = 10.2), the results highlighting a 
possible depressive symptomatology in 36.3% of our population
(score 17), and a probable depressive symptomatology in 22.0%
of our population (score 23). CONCLUSIONS: CVD has a great
impact on women. The SF-12 mean scores were below those of
the age- and gender-matched general population. Women with
CVD report greater risk of high depressive symptoms, compared
to the study of Rield where 23.1% of women did (CES-D score
16, age 65 to 75). The impact of CVD on patients daily life is
high even if it seems relative compared to the mean scores
obtained when initially validating the CIVIQ; for example for
patients suffering venous insufﬁciency of lower limb and arteri-
tis mean score was 53.08 (SD = 14.9), unfortunately compari-
son data with patients suffering CVD are lacking.
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OBJECTIVES: The objective of our study was to assess health
status among women suffering from CVD. METHODS: Symp-
tomatic women patients suffering from CVD (CEAP clinical
classes C0 to C4), aged over 18, newly treated by their GP with
a phlebotropic drug were enrolled in the study. Every patient
hadto complete a self-questionnaire including the SF-12 scale 
at day 0, day 3 and day 7. The SF-12 is a generic measure of
health statusThe SF-12 is composed of two dimensions, a Phys-
ical Component Summary (PCS-12) and a Mental component
Summary (MCS-12). The results are standardised on the general
US population (mean score of 50 (SD = 10)) so results for 1 can
be meaningfully compared with the other. The lower the score is
the worse is the impact on patients’ quality of life. RESULTS:
This analysis includes the ﬁrst 399 patients assessed at day 0,
day 3 and day 7. The mean age was 45.0 years old (SD = 11, n
= 370). At inclusion time (n = 374), MCS-12 and PCS-12 were
respectively 44.7 (SD = 10.6) and 46.4 (SD = 8.4): at day 3 and
day 7, these dimensions were respectively: D3: 46.5 (SD = 10.2)
and 46.2 (SD = 8.0) D7: 48.0 (SD = 10.3) and 46.2 (SD = 7.8).
For the mental dimension, the difference was statistically signif-
icant (p = 0.0001). CONCLUSIONS: These results suggest that
CVD has a great impact on women. The SF-12 mean scores were
below those of the age- and gender-matched general population.
The patient management and the use of a phlebotropic drug
demonstrated an improvement on the mental health status of the
patient and a decrease of the impact of pain interfering with
patients normal work.
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OBJECTIVES: The CAMPHOR is the ﬁrst patient-completed
instrument speciﬁc to Pulmonary Arterial Hypertension (PAH).
It consists of separate scales assessing Overall Symptoms (sub-
divided into Energy Level, Breathlessness and Mood sub-scales),
Physical Functioning and Quality of Life (QoL). We report 
ﬁndings from a validation study. METHODS: Patients were
recruited from Papworth Hospital, Cambridge, UK for a postal
survey. They completed the CAMPHOR and the Nottingham
Health Proﬁle (NHP) on the ﬁrst occasion, then two weeks later
completed the CAMPHOR and EQ-5D. Internal consistency was
